CYTALUX™for the Intraoperative Imaging of Prostate Cancer
A phase 2 trial of Pafolacianine in Prostate cancer, run by Indiana University, completed.
Overview
CYTALUX™for the Intraoperative Imaging of Prostate Cancer is a phase 2 interventional study registered as NCT06434909 by Indiana University, with 9 participants recorded, started 2024-09-19 and reaching its primary completion in 2025-09-04. Interventions recorded: Cytalux™ (pafolacianine) for fluorescent imaging, Image Guided Surgery. Conditions recorded: Prostate Cancer.
Linked to the drug Pafolacianine because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialSingle Dose Investigator Initiated Pilot Study to Investigate CYTALUX (Pafolacianine) for Intraoperative Detection of Malignant Tissue in Subjects Undergoing Surgical Resection for Cancer
Shares Pafolacianine and the tag pipeline.
- TrialELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
Shares Pafolacianine and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.
- TrialPhase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialEvaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
Shares Prostate cancer and the tag pipeline.
- TrialStudy of ACE-86225106 to Treat Patients With Advanced Solid Tumors
Shares Prostate cancer and the tag pipeline.
- TrialStudy of AZD0754 in Participants With Metastatic Prostate Cancer
Shares Prostate cancer and the tag pipeline.